French white biotech firm Lantana Bio and Danish biotech Biosyntia have signed an in-licensing deal for flavonoids.
Under this, they will jointly develop production processes for flavonoids for applications mainly in food but also personal care and other applications. Biosyntia will be responsible for bringing these processes into production and commercialising the ingredients.
Flavonoids are a group of actives that are present in several traditional Chinese medicine herbs with multiple claimed health benefits. The first to be developed is kaempferol, which will be the first fermented version on the world market.
“The jointly developed technology platform will deliver today’s commercial flavonoids in a sustainable and natural way, but over time it has the potential to deliver thousands of high-quality flavonoids not previously possible to produce,” Biosyntia said.
